Patients
| Country | Value | Year |
|---|---|---|
| France | 2.8 | 2024 |
| Germany | 2.3 | 2024 |
| Italy | 1.8 | 2024 |
| Russia | 2.0 | 2024 |
| Spain | 1.7 | 2024 |
| UK | 3.0 | 2024 |
Updated
Reviewed by Vidhi Upadhyay
Europe Newborn Screening Market Industry Trends and Forecast to 2034: Segmented by (Test, Technology, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$222.7 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $202.8 Mn | — | — |
| 2025 (base) | $219.2 Mn | +$16.4 Mn | — |
| 2026 (forecast) | $237.0 Mn | +$17.8 Mn | +8.1% |
| 2027 (forecast) | $256.2 Mn | +$19.2 Mn | +16.9% |
| 2028 (forecast) | $276.9 Mn | +$20.8 Mn | +26.3% |
| 2029 (forecast) | $299.4 Mn | +$22.4 Mn | +36.6% |
| 2030 (forecast) | $323.6 Mn | +$24.2 Mn | +47.6% |
| 2031 (forecast) | $349.8 Mn | +$26.2 Mn | +59.6% |
| 2032 (forecast) | $378.1 Mn | +$28.3 Mn | +72.5% |
| 2033 (forecast) | $408.8 Mn | +$30.6 Mn | +86.5% |
| 2034 (forecast) | $441.9 Mn | +$33.1 Mn | +101.6% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $219.2 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $441.9 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 8.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Test, technology and end user (see all) |
| Key players | Revvity, Natus Medical, Trivitron Healthcare, Bio-Rad Laboratories, Masimo Corporation (see all) |
| Regulator in Europe | EU MDRSource: European Commission, medical devices. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Newborn screening tests babies shortly after birth for rare but serious conditions such as metabolic, hormone and genetic disorders.
Key segments of the newborn Screening market include test (Dried Blood Spot Tests, Hearing Screening and Pulse Oximetry) and technology (Tandem Mass Spectrometry, Immunoassays and DNA Assays).
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the newborn Screening market.
Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the newborn Screening market room to grow, especially in emerging markets.
Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the newborn Screening market.
The newborn Screening market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first.[1] In the countries we cover here, medical devices are regulated by ANSM (France)[2], BfArM (Germany)[3], Ministry of Health (Italy)[4], Roszdravnadzor (Russia)[5], AEMPS (Spain)[6] and MHRA (UK)[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[8]
[1] European Commission, medical devices. Checked 14 Nov 2026.
[2] ANSM, French medicines agency. Checked 14 Nov 2026.
[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[4] Italian Ministry of Health. Checked 14 Nov 2026.
[5] Roszdravnadzor. Checked 14 Nov 2026.
[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
[8] European Commission, health technology assessment. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how newborn Screening products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Europe.
What doctors and scientists are doing in Newborn Screening right now, from free public sources.
| Country | Value | Year |
|---|---|---|
| France | 2.8 | 2024 |
| Germany | 2.3 | 2024 |
| Italy | 1.8 | 2024 |
| Russia | 2.0 | 2024 |
| Spain | 1.7 | 2024 |
| UK | 3.0 | 2024 |
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 17 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Europe · 1 shared keyword
Europe
Europe
Europe
Europe
Europe
Digital Health · Europe
Healthcare Services · Europe
Healthcare Services · Europe
Pharmaceuticals · Europe
Healthcare Services · Europe
Healthcare Services · Europe